SAN DIEGO--(BUSINESS WIRE)--MicroIslet, Inc. (MIIS.OB, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of transplantation therapies for diabetes, announced that it has met with the U.S. Food and Drug Administration (FDA) to discuss requirements for the filing of an Investigational New Drug (IND) application for MicroIslet-P™, a microencapsulated suspension of pancreatic islet cells.
